Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 7-8/2016

01.04.2016 | case report

Graves’ ophthalmopathy treated with protracted hypofractionated low-dose adaptive radiotherapy: case report and review of the literature

verfasst von: MD Ozan Cem Guler, MD Cem Onal, MSc Gungor Arslan

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 7-8/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Graves’ ophthalmopathy (GO) is the most common extra-thyroidal manifestation of Graves’ disease. The treatment options for GO are high-dose glucocorticoids, selenium, rituximab, cyclosporine, orbital radiotherapy (RT), and surgery. A 43-year-old male patient was referred to our clinic with complaints of severe bilateral proptosis, diplopia, and orbital pain at both globes for 1 year. Pretreatment magnetic resonance imaging revealed bilateral proptosis, the expansion of bilateral optic nerves sheath, the increase of right medial muscle thickness, and a mass at the right eyehole. Patient was treated with 1 Gy per fraction per week with a total dose of 10 Gy over 10 weeks with adoptive intensity-modulated radiotherapy technique. During RT at 3rd and 6th weeks, a moderate shrinkage of the lesions was observed. The patient has been disease free, has had no complaints for 36 months, and has not required any surgical intervention. No late side effects such as retinopathy or cataract were observed. Orbital RT with innovative techniques may be considered as an initial local treatment for GO. With adoptive protracted low dose RT, a good clinical and radiological response could be seen without increasing early and late reactions.
Literatur
2.
Zurück zum Zitat Matthiesen C, Thompson JS, Thompson D, et al. The efficacy of radiation therapy in the treatment of Graves’ orbitopathy. Int J Radiat Oncol Biol Phys. 2012;82(1):117–23. CrossRefPubMed Matthiesen C, Thompson JS, Thompson D, et al. The efficacy of radiation therapy in the treatment of Graves’ orbitopathy. Int J Radiat Oncol Biol Phys. 2012;82(1):117–23. CrossRefPubMed
3.
Zurück zum Zitat Kouloulias V, Kouvaris J, Zygogianni A, et al. Efficacy and toxicity of radiotherapy for Graves’ ophthalmopathy: the University of Athens experience. Head Neck Oncol. 2013;5(2):12. Kouloulias V, Kouvaris J, Zygogianni A, et al. Efficacy and toxicity of radiotherapy for Graves’ ophthalmopathy: the University of Athens experience. Head Neck Oncol. 2013;5(2):12.
4.
Zurück zum Zitat Li Yim JF, Sandinha T, Kerr JM, et al. Low dose orbital radiotherapy for thyroid eye disease. Orbit. 2011;30(6):269–74. CrossRef Li Yim JF, Sandinha T, Kerr JM, et al. Low dose orbital radiotherapy for thyroid eye disease. Orbit. 2011;30(6):269–74. CrossRef
5.
Zurück zum Zitat Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284–90. CrossRefPubMed Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284–90. CrossRefPubMed
6.
Zurück zum Zitat Kim JM, LaBree L, Levin L, et al. The relation of Graves’ ophthalmopathy to circulating thyroid hormone status. Br J Ophthalmol. 2004;88(1):72–4. CrossRefPubMedPubMedCentral Kim JM, LaBree L, Levin L, et al. The relation of Graves’ ophthalmopathy to circulating thyroid hormone status. Br J Ophthalmol. 2004;88(1):72–4. CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Kozaki A, Inoue R, Komoto N, et al. Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases. Optom Vis Sci. 2010;87(3):200–4. CrossRefPubMed Kozaki A, Inoue R, Komoto N, et al. Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases. Optom Vis Sci. 2010;87(3):200–4. CrossRefPubMed
8.
Zurück zum Zitat Marcocci C, Marino M. Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):325–37. CrossRefPubMed Marcocci C, Marino M. Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):325–37. CrossRefPubMed
9.
Zurück zum Zitat Cardoso CC, Giordani AJ, Wolosker AM, et al. Protracted hypofractionated radiotherapy for Graves’ ophthalmopathy: a pilot study of clinical and radiologic response. Int J Radiat Oncol Biol Phys. 2012;82(3):1285–91. CrossRefPubMed Cardoso CC, Giordani AJ, Wolosker AM, et al. Protracted hypofractionated radiotherapy for Graves’ ophthalmopathy: a pilot study of clinical and radiologic response. Int J Radiat Oncol Biol Phys. 2012;82(3):1285–91. CrossRefPubMed
10.
Zurück zum Zitat Dolman PJ, Rath S. Orbital radiotherapy for thyroid eye disease. Curr Opin Ophthalmol. 2012;23(5):427–32. CrossRefPubMed Dolman PJ, Rath S. Orbital radiotherapy for thyroid eye disease. Curr Opin Ophthalmol. 2012;23(5):427–32. CrossRefPubMed
11.
Zurück zum Zitat Nguyen NP, Krafft SP, Vos P, et al. Feasibility of tomotherapy for Graves’ ophthalmopathy: dosimetry comparison with conventional radiotherapy. Strahlenther Onkol. 2011;187(9):568–74. CrossRefPubMed Nguyen NP, Krafft SP, Vos P, et al. Feasibility of tomotherapy for Graves’ ophthalmopathy: dosimetry comparison with conventional radiotherapy. Strahlenther Onkol. 2011;187(9):568–74. CrossRefPubMed
12.
Zurück zum Zitat Stan MN, Garrity JA, Bradley EA, et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2006;91(12):4817–24. CrossRefPubMed Stan MN, Garrity JA, Bradley EA, et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2006;91(12):4817–24. CrossRefPubMed
13.
Zurück zum Zitat Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2004;89(12):5910–5. CrossRefPubMed Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2004;89(12):5910–5. CrossRefPubMed
14.
Zurück zum Zitat Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326(26):1733–8. CrossRefPubMed Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326(26):1733–8. CrossRefPubMed
15.
Zurück zum Zitat Hiromatsu Y, Eguchi H, Tani J, et al. Graves’ ophthalmopathy: epidemiology and natural history. Intern Med. 2014;53(5):353–60. CrossRefPubMed Hiromatsu Y, Eguchi H, Tani J, et al. Graves’ ophthalmopathy: epidemiology and natural history. Intern Med. 2014;53(5):353–60. CrossRefPubMed
16.
Zurück zum Zitat Micke O, Seegenschmiedt MH, German Working Group on Radiotherapy in G. Consensus guidelines for radiation therapy of benign diseases: a multicenter approach in Germany. Int J Radiat Oncol Biol Phys. 2002;52(2):496–513. CrossRefPubMed Micke O, Seegenschmiedt MH, German Working Group on Radiotherapy in G. Consensus guidelines for radiation therapy of benign diseases: a multicenter approach in Germany. Int J Radiat Oncol Biol Phys. 2002;52(2):496–513. CrossRefPubMed
17.
Zurück zum Zitat Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 2008;18(3):333–46. CrossRefPubMed Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 2008;18(3):333–46. CrossRefPubMed
18.
Zurück zum Zitat Kahaly GJ, Rosler HP, Pitz S, et al. Low- versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab. 2000;85(1):102–8. PubMed Kahaly GJ, Rosler HP, Pitz S, et al. Low- versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab. 2000;85(1):102–8. PubMed
Metadaten
Titel
Graves’ ophthalmopathy treated with protracted hypofractionated low-dose adaptive radiotherapy: case report and review of the literature
verfasst von
MD Ozan Cem Guler
MD Cem Onal
MSc Gungor Arslan
Publikationsdatum
01.04.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 7-8/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0870-z

Weitere Artikel der Ausgabe 7-8/2016

Wiener klinische Wochenschrift 7-8/2016 Zur Ausgabe